Comparative Cardiovascular Outcomes of Dapagliflozin Versus Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis

Cureus · PMC12050029

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, a significant interaction was detected in the heart failure subgroup (p = 0.04), where patients with heart failure showed a trend toward reduced MACE risk with empagliflozin compared to dapagliflozin (RR: 0.90, 95% CI: 0.82 to 1.00, I2 = 19%), while no such trend was observed in patients without heart failure (RR: 1.02, 95% CI: 0.97 to 1.07, I2 = 9%).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.